# Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia

> **NCT03559387** · PHASE2 · TERMINATED · sponsor: **Prolong Pharmaceuticals** · enrollment: 9 (actual)

## Conditions studied

- Chemotherapy-induced Neutropenia

## Interventions

- **DRUG:** ANF-RHO™
- **DRUG:** Neulasta®

## Key facts

- **NCT ID:** NCT03559387
- **Lead sponsor:** Prolong Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-03
- **Primary completion:** 2018-04-18
- **Final completion:** 2018-05-22
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Study redesign
- **Last updated:** 2019-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03559387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03559387, "Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03559387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*